Abrégé

Medical devices are described for performing mapping, ablating, and/or pacing procedures on one or more layers of the cardiac wall via an epicardial approach in a minimally invasive (e.g., orthoscopic) surgical procedure. One of the medical devices described includes a main support member and one or more secondary support members extending outwardly from the main support member having electrodes configured to receive electrical impulses. The secondary support member may include a support pad configured to be removably attached to a corresponding area of the epicardium for holding the medical device in place during a procedure, such as through application of vacuum pressure via a containment dome provided on each secondary support member. Further, an ablating electrode may be slidably disposed along the main support member for transmitting energy to a target site proximate the electrode. Associated methods are also described.

Classes IPC  ?

• A61B 18/14 - Sondes ou électrodes à cet effet
• A61B 5/042 - Electrodes spécialement adaptées à cet effet pour l'introduction dans le corps
• A61B 5/0408 - Electrodes spécialement adaptées à cet effet
• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
• A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
• A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
• A61N 1/06 - Électrodes pour traitement à haute fréquence

Abrégé

Devices, systems, and methods for treating cardiac arrhythmias are disclosed. An exemplary device includes a support member having a first end and a second. At least a first pacing electrode is located proximate the first end of the support member and at least a second pacing electrode is located proximate the second end of the support member. A defibrillating electrode is located between the first pacing electrode and the second pacing electrode. An exemplary method of treating a patient comprises a device for treating cardiac arrhythmias and placing the device adjacent a heart of the patient.

Classes IPC  ?

• A61B 5/042 - Electrodes spécialement adaptées à cet effet pour l'introduction dans le corps
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 18/14 - Sondes ou électrodes à cet effet
• A61N 1/00 - ÉlectrothérapieCircuits à cet effet
• A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
• A61N 1/362 - Stimulateurs cardiaques

Abrégé

The invention relates to synthetic polynucleotides encoding fukutin related protein (FKRP). The invention further relates to nucleic acid constructs comprising the synthetic polynucleotides and methods of using these synthetic polynucleotides to treat dystroglycanopathy disorders.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/861 - Vecteurs adénoviraux
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire

Abrégé

Delivery devices and vascular devices are described for addressing a target site within a body lumen. The delivery device includes one or more ultrasound transducers positioned to transmit and receive ultrasound signals so as to provide an image of an interior of the patient's blood vessel within which the vascular device is disposed in real time, as the procedure is taking place. Using the images provided by the ultrasound transducers, the longitudinal and rotational position of the delivery device (and the vascular device constrained therein) may be adjusted to align the vascular device with the patient's vasculature. In some examples, the vascular device being delivered includes fenestrations, whereas in others the vascular device integral branch grafts.

Classes IPC  ?

• A61B 8/08 - Applications cliniques
• A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
• A61B 8/12 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores dans des cavités ou des conduits du corps, p. ex. en utilisant des cathéters
• A61M 25/00 - CathétersSondes creuses
• A61B 19/00 - Instruments, outillage ou accessoires pour la chirurgie ou le diagnostic non couverts par l'un des groupes A61B 1/00-A61B 18/00, p.ex. pour stéréotaxie, opération aseptique, traitement de la luxation, protecteurs des bords des blessures(masques de protection du visage A41D 13/11; blouses de chirurgien ou vêtements pour malades A41D 13/12; dispositifs pour retirer, traiter ou transporter les liquides du corps A61M 1/00)
• A61B 1/313 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour l'introduction dans des incisions chirurgicales, p. ex. laparoscopes

Abrégé

The present invention provides compounds of Formula I or Formula II: wherein: T, V, W, Y and Z are each independently selected from the group of substituents described herein, and X is a tinker as further described herein. The present invention further provides compositions and conjugates including the compounds as well as methods of using these compounds including, but not limited to, methods of preventing, treating and/or diagnosing genetic disorders, such as muscular dystrophy, or non-genetic disorders as described herein.

Classes IPC  ?

• A01N 43/66 - Triazines-1,3,5 non hydrogénées et non substituées sur les atomes d'azote du cycle
• A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
• A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés

Abrégé

A device (100) for supporting a valve annulus is described that includes spaced apart support members (105) and a connecting member (110) extending between and connecting the support members. At least one adjustor (115) is also provided that is engaged with the connecting member and can be actuated to modify a length of the connecting member between two adjacent support members. In addition, each support member may include at least two channels extending through the support members at different heights with respect to an overall thickness of the respective support member. Each channel may receive a portion of the connecting member therethrough, and each support member may further include a passageway between the channels to allow selection of one of the channels. In this way, the device may be adjusted in at least two dimensions to support the valve leaflets and promote sufficient closure of the leaflets.

Classes IPC  ?

• A61F 2/24 - Valvules de cœur

Abrégé

A vascular device and method for positioning a vascular device within a patient's vasculature for use in extracorporeal membrane oxygenation (ECMO) are described that make use of one or more ultrasound transducers supported by the vascular device to visualize the location and orientation of the vascular device. An ultrasound transducer may be provided at a port of the vascular device that infuses oxygenated blood into the patient's vasculature to allow the operator of the vascular device to align the port with a particular structure in the patient's body, such as the tricuspid valve of the heart. Another ultrasound transducer may additionally or alternatively be provided at a distal end of the vascular device to facilitate insertion of the vascular device with minimal injury or trauma to the patient and to allow advancement of the device to the correct location. The imaging may be continuous and may be provided in real-time.

Classes IPC  ?

• A61B 8/12 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores dans des cavités ou des conduits du corps, p. ex. en utilisant des cathéters
• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
• A61M 1/16 - Systèmes de dialyseReins artificielsOxygénateurs du sang avec membranes

Abrégé

A device, system, and method that may help reduce complications associated with placing an intrauterine balloon in the uterine cavity of a patient is provided. In one aspect, the system includes an inflatable balloon, an inflation line having a distal end in communication with the balloon; an inner member comprising an elongate tubular body having a distal and proximal end; a slot extending from the distal to proximal end of the inner member, and an outer sheath in which the inner member is removably insertable. The outer sheath is configured to receive the balloon in a furled state therein such that the balloon may be introduced into the uterine cavity by transvaginally inserting the outer sheath through an endocervical canal of the patient and then introducing the balloon into the uterine cavity by moving the inner member through the outer sheath in the direction of uterine cavity.

Classes IPC  ?

• A61B 17/42 - Instruments ou procédés de gynécologie ou d'obstétrique
• A61F 6/12 - Dispositifs pour les introduire ou les enlever
• A61F 6/18 - Dispositifs pour les introduire ou les enlever

Abrégé

Systems, devices, and methods for longitudinal closure of a dissected sternum are provided. The system includes first and second reinforcing members, fasteners, and closure members. Each reinforcing member is configured to be placed on an outer surface of a respective sternum portion, such that each reinforcing member is longitudinally disposed on an opposite side of a sternum opening with respect to the other reinforcing member. Fasteners may be placed in holes defined in the reinforcing members to secure a respective reinforcing member to a corresponding sternum portion. The closure members, which may be sternal closing wires, may then be wrapped around the sternum portions and the reinforcing members transversely to close the sternum opening. Because the reinforcing members include extended regions having lateral edges that extend away from a midline of the respective reinforcing member, the closure members are moved away from the edges of the bone.

Classes IPC  ?

• A61B 17/80 - Plaques corticales
• A61B 17/82 - Dispositifs de fixation interne pour le cerclage des os

Abrégé

A system for supporting ribs is provided that includes first and second reinforcing members, fasteners, and closure members. Each reinforcing member may be attached to a respective rib via fasteners such that the reinforcing member spans one or more fractures of the ribs. In addition to individually holding the portions of the rib bone together to allow the fracture to heal, however, the reinforcing members may be used on rib pairs such that closure members may be wrapped around or extended between the rib pair in an effort to stabilize the ribs. By providing extended regions configured to receive closure members, healing of the ribs may be promoted and facilitated without creating unnecessary other pain to the patient, as the rounded portions serve to keep the closure members away from the neurovascular bundles associated with the ribs.

Classes IPC  ?

• A61B 17/70 - Dispositifs de mise en position ou de stabilisation de la colonne vertébrale, p. ex. stabilisateurs comprenant un liquide de remplissage dans un implant
• A61B 17/80 - Plaques corticales

Abrégé

A surgical drape (100) is described that is aimed at providing a way to direct a maximum amount of fluid (e.g., distention fluid) discharged from the patient's uterine cavity to a collection point, such as a fluid management system, during a hysteroscopic procedure. The surgical drape may include a cover portion (105) and a collection portion (110) that is attached to the cover portion (105). The cover portion (105) may define an opening (115) that provides a surgeon with surgical access to the patient for performing a medical procedure. The collection portion (110) may include a main panel (120) that can be attached to the patient's back distally of the gluteal cleft (e.g., via an adhesive strip). The main panel (110) may include a pocket (170), via which the surgeon may insert his hands to position the main panel (110) under the patient without disturbing the sterile field.

Classes IPC  ?

• A61B 19/08 - Draps de chirurgie
• A61B 17/42 - Instruments ou procédés de gynécologie ou d'obstétrique
• A61B 19/10 - avec des moyens pour maintenir ou porter les instruments chirurgicaux
• A61B 19/00 - Instruments, outillage ou accessoires pour la chirurgie ou le diagnostic non couverts par l'un des groupes A61B 1/00-A61B 18/00, p.ex. pour stéréotaxie, opération aseptique, traitement de la luxation, protecteurs des bords des blessures(masques de protection du visage A41D 13/11; blouses de chirurgien ou vêtements pour malades A41D 13/12; dispositifs pour retirer, traiter ou transporter les liquides du corps A61M 1/00)

Abrégé

A penetrator device (12), system (10), and associated method are provided that may help inform an operator of the position of a penetrating edge of the penetrator device within a subject. In one aspect, a penetrator device, such as a needle (12a), probe, cannula, or the like, includes an optical imaging system (14) that is configured to identify the position of a penetrating end of the penetrator device in a subject based on optical data received by the optical imaging system. The system is configured to identify the position of the penetrator device and provide a signal that alerts the operator to the position of the device within the subject.

Classes IPC  ?

• A61B 17/34 - TrocartsAiguilles à ponction
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 19/00 - Instruments, outillage ou accessoires pour la chirurgie ou le diagnostic non couverts par l'un des groupes A61B 1/00-A61B 18/00, p.ex. pour stéréotaxie, opération aseptique, traitement de la luxation, protecteurs des bords des blessures(masques de protection du visage A41D 13/11; blouses de chirurgien ou vêtements pour malades A41D 13/12; dispositifs pour retirer, traiter ou transporter les liquides du corps A61M 1/00)
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux

Abrégé

A passively flexible ureteroscope having a diameter of less than about 2.5 millimeters is provided. The ureteroscope may help overcome many of the problems associated with the prior art devices and methods for removing kidney stones. The ureteroscope includes an elongate member having a distal portion, a proximal portion, and an inner conduit that extends longitudinally between the proximal and distal portions. The elongate member is made from a passively flexible material that is capable of being inserted and directed through a patient's body cavity, such as the ureter, by manual direction and pressure so that minimal, if any, additional mechanical or steering mechanisms are present. An imaging device and light source are provided at the distal portion of the elongate member to allow for positioning the device with respect to the stone. A laser fiber can be directed through the conduit to destroy a targeted stone.

Classes IPC  ?

• A61B 1/307 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour l'appareil urinaire, p. ex. urétroscopes, cystoscopes
• A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
• A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
• A61B 19/00 - Instruments, outillage ou accessoires pour la chirurgie ou le diagnostic non couverts par l'un des groupes A61B 1/00-A61B 18/00, p.ex. pour stéréotaxie, opération aseptique, traitement de la luxation, protecteurs des bords des blessures(masques de protection du visage A41D 13/11; blouses de chirurgien ou vêtements pour malades A41D 13/12; dispositifs pour retirer, traiter ou transporter les liquides du corps A61M 1/00)

Abrégé

Devices and methods are described for treating a mitral valve defect. The device described includes features that allow the device to conform to the actual pathology of the valve, rather than attempting to replicate a healthy valve (which the patient does not have). In this way, the device allows the patient's actual valve to work as well as possible, given the valve's diseased condition. The actual pathology of the valve is accommodated by providing for multiple dimensions of adjustability of the device, including adjustability of the size (e.g., diameter) of the device as well as adjustability of the elevation or inclination of one portion of the device (e.g., the portion supporting the posterior leaflet) with respect to another portion of the device.

Classes IPC  ?

• A61F 2/24 - Valvules de cœur

Abrégé

A system and method for measuring a subject's blood pressure is provided. The system includes a sphygmomanometer cuff configured to apply a pressure to a blood vessel region so as to restrict the flow of blood through a blood vessel of the blood vessel region; at least one transducer configured to transmit a signal toward the blood vessel region and to detect a return signal indicative of a velocity of blood flow through the blood vessel; and an apparatus having a processor configured to determine a systolic blood pressure of the subject. The processor is configured to determine whether the return signal corresponds to a first Korotkoff sound of the blood flow through the blood vessel, reduce pressure applied via the sphygmomanometer cuff if the return signal does not correspond to the first Korotkoff sound, and determine pressure applied via the sphygmomanometer cuff when the return signal corresponds to the first Korotkoff sound.

Classes IPC  ?

• A61B 5/022 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par application d'une pression pour fermer les vaisseaux sanguins, p. ex. contre la peauOphtalmodynamomètres
• A61B 5/0225 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par application d'une pression pour fermer les vaisseaux sanguins, p. ex. contre la peauOphtalmodynamomètres la pression étant commandée par des signaux électriques, p. ex. dérivés des bruits de Korotkoff
• A61B 5/026 - Mesure du débit sanguin
• A61B 5/0285 - Mesure de la vitesse de propagation de l'onde pulsatile
• A61B 8/06 - Mesure du débit sanguin
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The present invention is directed to compositions and associated methods for treatment, prevention, amelioration, and/or delaying the onset of hepatic fibrosis and/or associated diseases. The methods preferably involve regulating at least one of Rev-erbα expression, activity, and subcellular localization. In particular, certain embodiments of the present invention relate to compositions and methods of using a Rev-erb-modulating agent (REMA) for the treatment or prevention of hepatic fibrosis and/or associated diseases. Preferably, the amount of a REMA administered comprises a quantity sufficient to modulate at least one of Rev-erbα expression, activity, and subcellular localization and reduce the activation of hepatic stellate cells (HSCs).

Classes IPC  ?

• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament

Abrégé

The present invention provides methods for treating or preventing portal hypertension comprising administering to a patient in need of such treatment or prevention at least one Rev-erb modulating agent (REMA) in an amount effective to treat or prevent said portal hypertension. The REMA can be SR6452 or a related compound, such as SR9009 or SR9011. The amount of the REMA administered can comprises a quantity sufficient to modulate Rev-erbα expression, activity, and/or subcellular location and/or to inhibit or reverse hepatic stellate cell (HSC) activation and contractility.

Classes IPC  ?

• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament

Abrégé

Methods and kits for characterizing liver damage in an individual are provided. The methods employ the use of immune analytes as biomarkers for detecting liver damage and predicting the likelihood that an individual suffering from liver damage will experience life-threatening liver failure. Concentration values for serum albumin and other identified immune analytes are obtained or determined from a blood sample taken from the individual. The obtained concentration values are then compared to corresponding concentrations from individuals having a healthy liver. By comparing the concentrations, an individual's likelihood of developing life-threatening liver failure and needing a liver transplant within a given time period (e.g., 6 months) can be identified.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

Medical devices are described for performing mapping, ablating, and/or pacing procedures on one or more layers of the cardiac wall via an epicardial approach in a minimally invasive (e.g., orthoscopic) surgical procedure. One of the medical devices described includes a main support member and one or more secondary support members extending outwardly from the main support member having electrodes configured to receive electrical impulses. The secondary support member may include a support pad configured to be removably attached to a corresponding area of the epicardium for holding the medical device in place during a procedure, such as through application of vacuum pressure via a containment dome provided on each secondary support member. Further, an ablating electrode may be slidably disposed along the main support member for transmitting energy to a target site proximate the electrode. Associated methods are also described.

Classes IPC  ?

• A61B 18/14 - Sondes ou électrodes à cet effet
• A61N 1/06 - Électrodes pour traitement à haute fréquence

Abrégé

Vascular devices and methods for addressing aortic pathologies are provided that facilitate hemostasis at the junctions of the ends of the device with the native aorta or other vessels to minimize or eliminate the risk of endoleaks. One or both ends of the device may include inner and outer skirts that are configured to receive a section of native blood vessel there between. The outer skirt may be flared in some cases or rolled up prior to placement at and engagement with the blood vessel to provide clearance for joining the blood vessel to the inner skirt of the device, such as via sutures. Once engaged, the outer skirt is disposed such that the blood vessel is between the inner and outer skirts. Devices and associated methods are also described that allow endografts to be deployed and engaged with an end of the device in areas with insufficient landing zones.

Classes IPC  ?

• A61F 2/06 - Vaisseaux sanguins

Abrégé

Systems, devices, and methods for longitudinal closure of a dissected sternum are provided. The system includes first and second reinforcing members, fasteners, and closure members. Each reinforcing member is configured to be placed on an outer surface of a respective sternum portion, such that each reinforcing member is longitudinally disposed on an opposite side of a sternum opening with respect to the other reinforcing member. Fasteners may be placed in holes defined in the reinforcing members to secure a respective reinforcing member to a corresponding sternum portion. The closure members, which may be sternal closing wires, may then be wrapped around the sternum portions and the reinforcing members transversely to close the sternum opening. The system provides for a low installed profile, enhancing patient comfort and facilitating healing, and also provides for quick and easy access to the thoracic cavity for re-do sternotomies, if needed.

Classes IPC  ?

• A61B 17/80 - Plaques corticales
• A61B 17/82 - Dispositifs de fixation interne pour le cerclage des os

Abrégé

Systems, devices, and methods for longitudinal closure of a dissected sternum are provided. The system includes first and second reinforcing members, fasteners, and closure members. Each reinforcing member is configured to be placed on an outer surface of a respective sternum portion, such that each reinforcing member is longitudinally disposed on an opposite side of a sternum opening with respect to the other reinforcing member. Fasteners may be placed in holes defined in the reinforcing members to secure a respective reinforcing member to a corresponding sternum portion. The closure members, which may be sternal closing wires, may then be wrapped around the sternum portions and the reinforcing members transversely to close the sternum opening. The system provides for a low installed profile, enhancing patient comfort and facilitating healing, and also provides for quick and easy access to the thoracic cavity for re-do sternotomies, if needed.

Classes IPC  ?

• A61B 17/82 - Dispositifs de fixation interne pour le cerclage des os
• A61B 17/80 - Plaques corticales

Abrégé

Assemblies, devices, and methods for positioning the same proximate a target site within a body lumen are provided. The assembly (100) includes first and second components (110, 120) that can function independently of one another to address a patient's vascular abnormalities or can cooperate to form an assembly. The assembly is designed to address aortic pathologies near clusters of arterial branches in a way that allows blood to continue flowing to the arterial branches during the procedure while providing an adequate landing zone for the adjoining component. One of the components may include a tapered portion (160) near one end that can be received by a corresponding end of the other component. Alternatively, one of the components may include an invaginated end that is able to receive a corresponding end of the other component such that the position of each component is substantially fixed with respect to the other.

Classes IPC  ?

• A61F 2/06 - Vaisseaux sanguins

Abrégé

Assemblies, devices, and methods for positioning the same proximate a target site within a body lumen are provided. The assembly (100) includes first and second components (110, 120) that can function independently of one another to address a patient's vascular abnormalities or can cooperate to form an assembly. The assembly is designed to address aortic pathologies near clusters of arterial branches in a way that allows blood to continue flowing to the arterial branches during the procedure while providing an adequate landing zone for the adjoining component. One of the components may include a tapered portion (160) near one end that can be received by a corresponding end of the other component. Alternatively, one of the components may include an invaginated end that is able to receive a corresponding end of the other component such that the position of each component is substantially fixed with respect to the other.

Classes IPC  ?

• A61F 2/06 - Vaisseaux sanguins

Abrégé

Amphiphilic cationic polymers comprising a biocompatible amphiphile linked to an organic cation are provided. The polymers complex with therapeutic agents and facilitate delivery of such therapeutic agents, particularly therapeutic nucleic acids, both in vitro and in vivo. Accordingly, the invention further provides methods of facilitating delivery of therapeutic and/or diagnostic agents to a cell and methods of treating a condition, such as a disease or infection, in an organism using the amphiphilic cationic polymers of the invention.

Classes IPC  ?

• A61K 9/107 - Émulsions
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire

Abrégé

The present invention provides a method for treating or preventing fibrosis comprising administering to a patient in need of such treatment or prevention an amount of microRNA-19b effective to treat or prevent said fibrosis. In some embodiments, the invention relates to inhibiting the activation of collagen-producing cells and thereby treating or preventing fibrosis. The methods of the invention also include detection of biomarkers that can be used to diagnose disease and/or evaluate the prognosis of a patient suffering from fibrosis or at risk of developing fibrosis, such as hepatic fibrosis. Such methods may be used to characterize the progression of diseases associated with fibrosis.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

Embodiments of the present invention are directed generally to antisense compounds and compositions for the treatment of muscular dystrophy, and in particular, Duchenne muscular dystrophy (DMD). In one embodiment, the invention is directed to antisense oligonucleotide molecules, pharmaceutical compositions and formulations comprising antisense oligonucleotide molecules, and methods of treating muscular dystrophy related diseases and disorders wherein the antisense oligonucleotide molecules comprises a base sequence selected from the group consisting of SEQ ID NO: 5-8, 10, 12, 14, 16, 24, 27, 28, 34, 35, 37, 40, 42, 44-46, 79, 97, 100, 101, and 1 16, and combinations thereof.

Classes IPC  ?

• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire

Abrégé

The present invention relates to compositions and methods for the preparation, stabilization, and/or storage of active agents, particularly therapeutic proteins and polypeptides such as Interleukin-2.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• G01N 1/00 - ÉchantillonnagePréparation des éprouvettes pour la recherche

Abrégé

A method and a test for using carbonic anhydrase (CA), particularly CA-I or CA-II, as a biomarker of hemolysis. The method and test detect hemolysis by determining a percentage erythrocyte hemolysis in a specimen or sample of blood based upon quantification of carbonic anhydrase present in the extracellular portion of the blood. The method and test serve to optimize therapeutic efficacy for treatments of hemolysis. Plasma carbonic anhydrase is used to determine the percentage hemolysis in plasma. Furthermore, CA is quantified with specificity to the isozyme present in the plasma.

Classes IPC  ?

• B01D 53/62 - Oxydes de carbone
• B01D 53/77 - Procédés en phase liquide

Abrégé

The present invention is directed to methods of delivering macromolecules to a target cell or tissue by microwave irradiation. A target cell or tissue is exposed to one or more macromolecules to be delivered into the desired cell or tissue and irradiated with microwave radiation. The strength or power of the microwave radiation is such that the macromolecules are delivered into the target cell or tissue. Preferably, the strength of the microwave radiation does not significantly impact cell viability in a negative manner (e.g., apoptosis).

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The present invention provides a method for the treatment of a disease or disorder related to an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a metal and a thiol. In particular, embodiments of the present invention are directed towards methods of treating inflammatory conditions that are associated with elevated levels of free TNFα. In one embodiment, the present invention can be used to treat and/or ameliorate the effects of a wide variety of diseases or disorders related to an inflammatory condition including one or more of the following inflammation related diseases/disorders: arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome, chronic obstructive respiratory diseases (COPD), fibromyalgia and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.

Classes IPC  ?

• A61K 31/095 - Composés du soufre, du sélénium ou du tellure, p. ex. thiols
• A61K 31/29 - Composés de l'antimoine ou du bismuth
• A61K 31/285 - Composés de l'arsenic
• A61K 33/24 - Métaux lourdsLeurs composés
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Apparatuses, systems, and methods are provided for growing and maintaining cells. A three-dimensional matrix, such as a hydrogel material, is seeded with cells and placed in a bioreactor having two compartments. The matrix is supported between the two compartments by first and second porous materials, which engage opposing surfaces of the matrix. A first media stream having certain properties is propagated through the first compartment, where it contacts one surface of the matrix via the first porous material. A second media stream having different properties is propagated through the second compartment such that it contacts the opposite surface of the matrix via the second porous material. Through migration of each stream at least partially into the matrix, various controlled gradients may be established within the matrix, encouraging growth of the cells. Such gradients include osmotic pressure, oscillating osmotic pressure, hydrostatic pressure, oxygen tension, and/or nutrient gradients.

Classes IPC  ?

• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse

Abrégé

A method for determining whether a subject has Gram negative bacterial pneumonia based on the presence of lipopolysaccharide in exhaled breath condensate collected from the subject. The collection devices utilized to collect exhaled breath condensate from both spontaneously breathing and mechanically ventilated subjects and the devices utilized to determine whether lipopolysaccharide is present in the collected exhaled breath condensate.

Classes IPC  ?

• A61B 5/08 - Dispositifs de mesure pour examiner les organes respiratoires
• G01N 1/22 - Dispositifs pour prélever des échantillons à l'état gazeux
• G01N 31/00 - Recherche ou analyse des matériaux non biologiques par l'emploi des procédés chimiques spécifiés dans les sous-groupesAppareils spécialement adaptés à de tels procédés
• G01N 33/497 - Analyse physique de matériau biologique de matériau biologique gazeux, p. ex. de l'haleine